Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Praxis Precision Medicines’s Essential1 Study Evaluating Ulixacaltamide (PRAX-944) For Essential Tremor Did Not Reach Statistical Significance On Primary Endpoint, Change From Baseline To Day 56 In The Modified Activities Of Daily Living (mADL) Score

Ulixacaltamide demonstrated improvement in modified Activities of Daily Living (mADL) primary efficacy endpoint relative to placebo that did not reach statistical significance (p=0.126), and achieved nominal
byBenzinga Newsdesk
March 3, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0
  • Ulixacaltamide demonstrated improvement in modified Activities of Daily Living (mADL) primary efficacy endpoint relative to placebo that did not reach statistical significance (p=0.126), and achieved nominal statistical significance in TETRAS-ADL secondary endpoint (p=0.026)
  • Based upon observed efficacy and safety profile, Praxis intends to engage with the FDA in an end of Phase 2 meeting and initiate a ulixacaltamide Phase 3 study for the treatment of essential tremor in 2H23
     
 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts